MindMaze Therapeutics Holding (CHIX:MMTXZ) WACC %:6.85% (As of Jul. 02, 2026) — Near Median


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding WACC %?

MindMaze Therapeutics Holding CHIX:MMTXZ +4.74% 15 WACC % is 6.85% as of Jul. 02, 2026, which is 7% above its 10-year median of 6.38. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 1,424 Biotechnology companies, MindMaze Therapeutics Holding ranks better than 67.84% on this metric.

As of today (2026-07-02), MindMaze Therapeutics Holding's weighted average cost of capital is 6.85%%. MindMaze Therapeutics Holding's ROIC % is -46.33% (calculated using TTM income statement data). MindMaze Therapeutics Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


MindMaze Therapeutics Holding  (CHIX:MMTXz) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, MindMaze Therapeutics Holding's weighted average cost of capital is 6.85%%. MindMaze Therapeutics Holding's ROIC % is -46.33% (calculated using TTM income statement data). MindMaze Therapeutics Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.


Related Terms

MindMaze Therapeutics Holding WACC % Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding WACC % Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
WACC %
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
WACC % 0.00 0.00

CHIX:MMTXZ vs VRTX, REGN, ALNY: WACC % Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindMaze Therapeutics Holding WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's WACC % distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's WACC % falls into.


CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, MindMaze Therapeutics Holding's market capitalization (E) is CHF34.515 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, MindMaze Therapeutics Holding's latest one-year annual average Book Value of Debt (D) is CHF1.806 Mil.
a) weight of equity = E / (E + D) = 34.515 / (34.515 + 1.806) = 0.9503
b) weight of debt = D / (E + D) = 1.806 / (34.515 + 1.806) = 0.0497

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 0.44%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. MindMaze Therapeutics Holding's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 0.44% + 1 * 6% = 6.44%

3. Cost of Debt:
GuruFocus uses latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
As of Dec. 2025, MindMaze Therapeutics Holding's interest expense (positive number) was CHF0.266 Mil. Its total Book Value of Debt (D) is CHF1.806 Mil.
Cost of Debt = 0.266 / 1.806 = 14.7287%.

4. Multiply by one minus annual Tax Rate:
GuruFocus uses the most recent annual Tax Expense divided by the most recent annual Pre-Tax Income to calculate the tax rate. The calculated annual tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated annual Tax Rate = 0 / -9.906 = 0%.

MindMaze Therapeutics Holding's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9503*6.44%+0.0497*14.7287%*(1 - 0%)
=6.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 6.85% mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a WACC % of 6.85% as of Jul. 02, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on MindMaze Therapeutics Holding and its competitors. This is near median its historical median of 6.38. Over the past decade, MindMaze Therapeutics Holding's WACC % has ranged from 6.38 to 6.86. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #458 out of 1424 companies in the Biotechnology industry, placing it in the top 32.2%.
Is MindMaze Therapeutics Holding's WACC % too high?
MindMaze Therapeutics Holding's current WACC % of 6.85% is near median its 10-year median of 6.38. Over the past 10 years, this metric has ranged from a low of 6.38 to a high of 6.86. The Biotechnology industry median WACC % is 10.03. MindMaze Therapeutics Holding's value of 6.85% is 31.7% below this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #458 out of 1424 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #458 out of 1424 companies for WACC %. This puts MindMaze Therapeutics Holding in the upper half of its industry. The industry median WACC % is 10.03. MindMaze Therapeutics Holding's value of 6.85% is 31.7% below this benchmark. Historically, MindMaze Therapeutics Holding's own WACC % has ranged from 6.38 to 6.86 over the past decade. While the company's 10-year median is 6.38 vs. the industry median of 10.03, MindMaze Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.03, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current WACC % of 6.85% is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median WACC % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current WACC % is 6.85%, which is near median its own 10-year median of 6.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current WACC % of 6.85%. The current WACC % is 6.85%, which is near median its 10-year median of 6.38 and 31.7% below the Biotechnology industry median of 10.03. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current WACC % is 6.85% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price